Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Breast cancer presenting as parotid tumour - first reported case in literature.

Ramesh RS, Manjunath S, Ustad TH, Pais S, Shivakumar K.

Indian J Surg Oncol. 2010 Jan;1(1):76-7. doi: 10.1007/s13193-010-0015-9.

2.

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.

Olsson H, Borg A, Ewers SB, Fernö M, Möller T, Ranstam J.

Med Oncol Tumor Pharmacother. 1986;3(2):77-81.

PMID:
3747639
3.

Parotid gland metastasis of a breast cancer.

Perez-Fidalgo JA, Chirivella I, Laforga J, Colio JM, Blanes MD, Baydal R, Roselló S, De-la-Morena E, Lluch A.

Clin Transl Oncol. 2007 Apr;9(4):264-5.

PMID:
17462982
4.
5.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

6.

Metastatic involvement of parotid from carcinoma of the breast--a case report.

Dangore-Khasbage SB, Degwekar SS, Bhowate RR, Bhake A.

Oral Maxillofac Surg. 2009 Mar;13(1):49-53. doi: 10.1007/s10006-009-0146-8.

PMID:
19190940
7.

A rare 'parotid tumour'.

Ethell AT.

J Laryngol Otol. 1979 Jul;93(7):741-4.

PMID:
469404
8.

[Parotid metastases from breast cancer].

Szymański M, Siwiec H, Olszański W, Gołabek W.

Wiad Lek. 2002;55(7-8):494-7. Polish.

PMID:
12428580
9.
10.
11.

Histopathological findings in parotid gland metastases from renal cell carcinoma.

Mrena R, Leivo I, Passador-Santos F, Hagström J, Mäkitie AA.

Eur Arch Otorhinolaryngol. 2008 Sep;265(9):1005-9. doi: 10.1007/s00405-008-0679-8. Review.

PMID:
18438681
12.

Synchronous bilateral mucoepidermoid carcinoma of the parotid gland.

Hakuba N, Hyodo M.

J Laryngol Otol. 2003 May;117(5):419-21. Review.

PMID:
12803799
13.

Prostatic carcinoma presenting with painless parotid mass.

Kirkali Z, Koyuncuoğlu M, Pabuçcuoğlu U, Güneri A, Mungan U.

Urology. 1995 Sep;46(3):406-7.

PMID:
7544935
14.

Season of tumour detection influences factors predicting survival of patients with breast cancer.

Mason BH, Holdaway IM, Stewart AW, Neave LM, Kay RG.

Breast Cancer Res Treat. 1990 Jan;15(1):27-37.

PMID:
2328328
15.

Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.

Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC.

Cancer Res. 1979 May;39(5):1447-54.

16.

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.

17.
18.

Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.

Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, Naik GA, Gholap AS, Barsky SH.

J Microsc. 2007 Jun;226(Pt 3):244-55.

19.

Contralateral metastasis of parotid gland in advanced breast cancer with peripheral facial paralysis.

Sellinger M, Neubauer K, William M, Hemmerlein B, Friedrich M, Salehin D.

Arch Gynecol Obstet. 2011 Dec;284(6):1557-60. doi: 10.1007/s00404-011-1989-4.

PMID:
21822624
20.

Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer.

Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S.

Eur J Cancer. 1999 Feb;35(2):214-8.

PMID:
10448262

Supplemental Content

Support Center